Understanding the Future of Medicine and What it Means for Your Company

Crosstree’s advisors have end-to-end experience in the pharma services, research, and development space, and has worked with companies positioned from discovery and preclinical, to clinical development and lab services, to supply and commercialization.

As pharmaceutical companies shift toward combination product development programs and more complex test-and-treat therapies, patient-centricity has become a focal point. Crosstree understands how each company supports the patient’s journey — either directly or secondarily by facilitating better research and development — and can identify the most viable buyers based on current and emerging needs.

Crosstree has provided buy- and sell-side financial guidance through the rise of targeted medicine. Today, Crosstree is spearheading transactions for innovative growth companies and established market leaders shifting toward precision and specialty medicine strategies.

pharma-services-aud-chart-2

Click image to view larger

Bluebooks

Explore our industry-specific Bluebooks for comprehensive monthly coverage of M&A, recapitalization, and growth financing transactions, along with year-on-year comparisons. Subscribe to your relevant BlueBook for valuable insights today.

Pharma Services - BlueBook
Latest Pharma Services Transactions
Continuum Clinical, a BC Worldwide company, Acquired by Spectrum Science, a Portfolio Company of Knox Lane, to Bolster Patient Engagement Capabilities

Continuum Clinical, a BC Worldwide company, Acquired by Spectrum Science, a Portfolio Company of Knox Lane, to Bolster Patient Engagement Capabilities

Yecuris Corporation Acquired by Janvier Group to Expand Preclinical Service Offering Internationally

Yecuris Corporation Acquired by Janvier Group to Expand Preclinical Service Offering Internationally

Modular Devices, a Portfolio Company of O2 Investment Partners, Partners with Flow Clean Rooms and Supply to Bolster Existing Clean Room Manufacturing Capabilities and Expand Overall Offering

Modular Devices, a Portfolio Company of O2 Investment Partners, Partners with Flow Clean Rooms and Supply to Bolster Existing Clean Room Manufacturing Capabilities and Expand Overall Offering

Alpha IRB Acquired by Sabai Global, a Portfolio Company of Thompson Street Capital, to Expand IRB Capabilities

Alpha IRB Acquired by Sabai Global, a Portfolio Company of Thompson Street Capital, to Expand IRB Capabilities

Versiti Acquired Pearl Pathways to Expand Clinical Trial Services Capabilities

Versiti Acquired Pearl Pathways to Expand Clinical Trial Services Capabilities

VaxTRIALS Acquired by Emmes, a portfolio company of New Mountain Capital, to Expand Vaccine and Clinical Trial Site Capabilities

VaxTRIALS Acquired by Emmes, a portfolio company of New Mountain Capital, to Expand Vaccine and Clinical Trial Site Capabilities

Grant Avenue Capital Recapitalizes CREO

Grant Avenue Capital Recapitalizes CREO

Monroe Biomedical Research Acquired by New Harbor Capital in a First Step to Build-out a Clinical Research Site Platform

Monroe Biomedical Research Acquired by New Harbor Capital in a First Step to Build-out a Clinical Research Site Platform

SSI Strategy, a Portfolio Company of Amulet Capital Partners, Acquired NDA Group AB to Bolster Regulatory Affairs Consulting Capabilities and Expand Into the EU

SSI Strategy, a Portfolio Company of Amulet Capital Partners, Acquired NDA Group AB to Bolster Regulatory Affairs Consulting Capabilities and Expand Into the EU

Catalyst Clinical Research, a Portfolio Company of QHP Capital, Acquired Genpro Research to Expand Global Footprint and Deepen Service Offerings

Catalyst Clinical Research, a Portfolio Company of QHP Capital, Acquired Genpro Research to Expand Global Footprint and Deepen Service Offerings

Accel Research Sites Network Acquired by Alcanza Clinical Research, a portfolio company of Martis Capital, to Expand its Clinical Trial Site Network and Clinical Trial Execution Capabilities

Accel Research Sites Network Acquired by Alcanza Clinical Research, a portfolio company of Martis Capital, to Expand its Clinical Trial Site Network and Clinical Trial Execution Capabilities

Benchmark Research Acquired by IQVIA, combined with Avacare to Expand Vaccine and Clinical Trial Site Capabilities

Benchmark Research Acquired by IQVIA, combined with Avacare to Expand Vaccine and Clinical Trial Site Capabilities

Clinical Site Services and Patient Advertising Guru Acquired by American Clinical Research Services to Add Tech-Enabled Patient Recruitment Capabilities

Clinical Site Services and Patient Advertising Guru Acquired by American Clinical Research Services to Add Tech-Enabled Patient Recruitment Capabilities

ClinChoice Acquires CROMSOURCE to Expand CRO Capabilities Globally

ClinChoice Acquires CROMSOURCE to Expand CRO Capabilities Globally

anteris Acquired by Kymanox, a Portfolio Company of Westview Capital Partners, to Expand Injectable Combination Product Development Capabilities Globally

anteris Acquired by Kymanox, a Portfolio Company of Westview Capital Partners, to Expand Injectable Combination Product Development Capabilities Globally

OpenClinica Completes Growth Recapitalization with Thompson Street Capital Partners to Accelerate Enablement of Clinical Trials

OpenClinica Completes Growth Recapitalization with Thompson Street Capital Partners to Accelerate Enablement of Clinical Trials

Clairvest Acquires Boca Biolistics to Accelerate Growth of Infectious Disease and Oncological Biobanking Capabilities

Clairvest Acquires Boca Biolistics to Accelerate Growth of Infectious Disease and Oncological Biobanking Capabilities

RMC Pharmaceutical Solutions Acquired by Syner-G Biopharma Group, a Portfolio Company of Riverside Partners, to Expand Regulatory Compliance Solutions

RMC Pharmaceutical Solutions Acquired by Syner-G Biopharma Group, a Portfolio Company of Riverside Partners, to Expand Regulatory Compliance Solutions

Sabai Global Acquired by Thompson Street Capital Partners to Accelerate IBC and IRB Growth

Sabai Global Acquired by Thompson Street Capital Partners to Accelerate IBC and IRB Growth

LongueVue Capital Partners Acquires Majority Stake in Summit Clinical Research to Accelerate SMO/IRO Growth

LongueVue Capital Partners Acquires Majority Stake in Summit Clinical Research to Accelerate SMO/IRO Growth